Prostate Cancer

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

Enzalutamide plus androgen deprivation therapy demonstrated a statistically significant improvement in overall survival compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).

William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Thomas J. Polascik, MD, discusses the growing relevance of genetic testing for men with prostate cancer and those at a high risk of developing the disease.

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Darolutamide plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer, according to results from a preplanned final OS analysis of the phase III ARAMIS trial.